Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14222776 | 0.90 | GRIN1 (0.49) | NAMPTPRMT5WDR77GRIN1GRIN2A | |
| SCHEMBL4718116 | 0.81 | ITGB3 (0.53) | NAMPTPRMT5WDR77 | |
| SCHEMBL4718124 | 0.77 | ITGB3 (0.51) | NAMPT | |
| SCHEMBL4715032 | 0.77 | GRIN1 (0.41) | NAMPTPRMT5WDR77GRIN1GRIN2A | |
| SCHEMBL4714486 | 0.76 | SUCNR1 (0.41) | NAMPTPRMT5WDR77 | |
| SCHEMBL4716885 | 0.75 | SIGMAR1 (0.48) | PRMT5WDR77GRIN1GRIN2B | |
| SCHEMBL4720078 | 0.74 | ITGAV (0.57) | — | |
| SCHEMBL4715242 | 0.73 | GRIN1 (0.46) | PRMT5WDR77GRIN1GRIN2B | |
| SCHEMBL14222058 | 0.72 | NAMPT (0.46) | NAMPTPRMT5WDR77 | |
| SCHEMBL4714889 | 0.72 | ITGAV (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |